Skip to main content

Table 1 Baseline data on cases that later in life developed end-stage renal disease and referents

From: End-stage renal disease and low level exposure to lead, cadmium and mercury; a population-based, prospective nested case-referent study in Sweden

 

Cases

Referents

Difference between cases and referents with 95% confidence intervals/p-value

Cases and referents from both study populations

118

347

 

Number of men/women

66/52

194/153

 

Northern Sweden Health and Disease Study (NSHDS)

72

214

 

Malmoe Diet and Cancer Study (MDCS)

46

133

 

Characteristics at base-line examination, i.e. prior to diagnosis of end-stage renal disease:

Diabetes (y/n)

20 (21%)

8 (3%)

OR = 8.3a (3.5, 22)

Blood pressure (mm Hg), mean(standard deviation)

 Systolic (SBP)

141 (21.3)

135 (19.9)

5.8 a (1.5, 10)

 Diastolic (DBP)

85.8 (11.5)

83.1 (9.6)

2.7 a (0.42, 5.0)

 Hypertensionb (y/n)

66 (54.6%)

125 (34.8%)

OR = 2.2a (1.4, 3.5)

Smoking

  

p = 0.091a

      Never-smoker

34 (31%)

141 (41%)

 

      Not current smoker (undefined ex-smoker or never-smoker)

11 (10%)

38 (11%)

 

      Ex-smoker

26 (24%)

79 (23%)

 

      Current smoker

39 (35%)

82 (24%)

 

Mean age at baselinec (years)

63 (40–80)

63 (40–80)

 

Mean age at diagnosis of end-stage renal disease (years)

71 (46–87)

  

Time from baseline examination to development of end-stage renal disease (years)

7.7 (1–16)

  
  1. OR=odds ratio.
  2. aDifferences in binary variables were expressed as ORs with 95% confidence intervals, continues variables as the difference with 95% confidence intervals, and p-values using the chi-square test were reported for categorical variables with more than two levels.
  3. bHypertension was defined as SBP >140 or DBP > 90 mm Hg, or antihypertensive medication at baseline.
  4. cmatching factor.